Navigation Links
FDA Grants Orphan Drug Designation to Bayer's Investigational Compound Regorafenib for the Treatment of Gastrointestinal Stromal Tumors
Date:2/4/2011

WAYNE, N.J., Feb. 4, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. announced today that its investigational compound regorafenib (BAY 73-4506) has been granted orphan drug status for the treatment of patients with gastrointestinal stromal tumors (GIST) by the U.S. Food and Drug Administration (FDA).

Regorafenib is an investigational agent and is not approved by the FDA, the European Medicines Agency (EMA) or other Health Authorities.

"This is an important step in the overall development process for this investigational compound," said Kemal Malik, MD, Head of Global Development and member of the Bayer HealthCare Executive Committee.

In January, Bayer began enrolling patients in a randomized, double-blind, placebo-controlled Phase III study of regorafenib plus best supportive care versus placebo plus best supportive care for subjects with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite prior treatment with at least imatinib and sunitinib (NCT01271712). The trial is estimated to enroll 170 patients, who will be randomized in a 2:1 ratio to receive either regorafenib or placebo. Subjects receiving placebo who experience disease progression may be offered open-label regorafenib treatment (cross-over option).

The primary endpoint of this trial is progression-free survival (PFS), and secondary endpoints include overall survival (OS), time to progression (TTP), disease control rate (DCR), tumor response rate (RR), duration of response (DOR), and safety. All patients will enter the Survival Follow-Up Period upon discontinuation of study treatment, during which assessment of survival status will be performed every three months.

For information about this study, please visit www.clinicaltrials.gov (NCT01271712).

Orphan Drug Designation in the United States

In the United States, the Orphan Drugs Act (OD
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
2. Chinese SFDA Grants Immtech Fast Track Status
3. Ethics Group Asks USAID Inspector General to Investigate Legality of Grants to Soros Groups
4. NTMir Announces Research Grants for Epidemiology and Household Water as Source of Infection
5. FDA Grants Approval to Extend U.S. Enrollment and Clinical Trial
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. FDA Grants Priority Review for ACIPHEX(R) (rabeprazole sodium) sNDA for Short-Term Treatment of GERD in Adolescents
8. FDA Grants Priority Review for PROMACTA(R) (eltrombopag)
9. FDA Grants NeoVistas Request to Expand CABERNET Trial to 30 Sites in the U.S.
10. FDA Grants Market Clearance for the LipiScan(TM) Coronary Imaging System Developed by InfraReDx, Inc. - A Novel Spectroscopy System for the Identification of Lipid Core Containing Plaques of Interest in the Coronary Arteries
11. FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... May 28, 2015 Research and Markets ... Jain PharmaBiotech,s new report "Cardiovascular Drug Delivery ... offering. Drug delivery to the cardiovascular ... because of the anatomy and physiology of the ... all organs of the body. Drugs can be ...
(Date:5/29/2015)... and BOSTON , May ... in instrument development, custom automation, and contract manufacturing, and ... the Nanopatch™ needle-free drug delivery technology, have been named ... of the Nanopatch Jet Coating Instrument , an ... research and product development.  The award was announced last ...
(Date:5/29/2015)... and MENLO PARK, Calif. ... Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the ... commercializing proven cancer therapies in new orphan drug ... American Association of Cancer Research (AACR) Advances in ... for its lead product candidate VAL-083 ...
Breaking Medicine Technology:Global Cardiovascular Drug Delivery Market 2015 - Technologies, Markets and Companies 2Global Cardiovascular Drug Delivery Market 2015 - Technologies, Markets and Companies 3Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 2Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5
... VILLAGE, Nev., Nov. 2 PDL BioPharma, Inc. (PDL) ... on its previously disclosed $300 million securitization transaction intended ... royalties. Morgan Stanley & Co. Incorporated acted as ... terms of the securitization transaction, PDL sold to QHP ...
... Nov. 2 Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced ... 30, 2009 on Monday, November 9, 2009, following the close of ... conference call at 5:00 p.m. Eastern Time on the same day ... call will be available for two weeks following the event. ...
Cached Medicine Technology:PDL BioPharma Announces Closing of $300,000,000 Securitization Transaction 2Alexza to Announce 2009 Third Quarter Financial Results and Update Its AZ-004 NDA Status on Monday, November 9, 2009 2Alexza to Announce 2009 Third Quarter Financial Results and Update Its AZ-004 NDA Status on Monday, November 9, 2009 3
(Date:5/30/2015)... (PRWEB) May 30, 2015 AVT, the ... quality assurance, is joining forces with leading proofing solutions ... to the worldwide printing market. , Under ... new software engine for its offline inspection solutions, which ... printing industry and its varying production workflow setups and ...
(Date:5/30/2015)... 30, 2015 The results of a ... has a high potential to cause mesothelioma, regardless of ... now on the Surviving Mesothelioma website. , ... Medicine in Lodz, Poland found that, among the 138 ... 1970 and 2012, all of them happened at plants ...
(Date:5/30/2015)... May 30, 2015 EHO offers a ... Portal that gives hospices the ability to manage their ... of this business model, EHO has been able to ... to its clients and survive among the giants of ... management systems three years ago, it has simplified the ...
(Date:5/30/2015)... 30, 2015 Cyclist Barry Haarde ... for the World 2015: Piles of Miles” near ... awareness about hemophilia and encourage individuals to support ... , Save One Life supports nearly 1,200 impoverished ... countries through direct sponsorships, scholarships and micro-enterprise grants. ...
(Date:5/30/2015)... 30, 2015 This year the ... Pulmonary Horizons to offer one of the most diverse ... discuss successful practices to diagnose, treat and manage patients ... Pulmonary Horizons Conference is Interaction with Multidisciplinary Healthcare ... Overall Needs of Patients with COPD," said Brian W. ...
Breaking Medicine News(10 mins):Health News:AVT and Global Vision Collaborate to Offer Cutting-edge Offline Inspection Solutions for Printing Industry 2Health News:AVT and Global Vision Collaborate to Offer Cutting-edge Offline Inspection Solutions for Printing Industry 3Health News:New Study Finds Close Link Between Crocidolite Asbestos and Deadly Mesothelioma, According to Surviving Mesothelioma 2Health News:Barry Haarde Cycles 4,000 Miles Across the USA for Hemophilia 2Health News:Pulmonary Horizons 2nd Annual COPD Conference Miami Hilton Downtown, July 17-19, 2015 Patient Centered Cross-Continuum Education to Improve the Care of Patients with COPD 2Health News:Pulmonary Horizons 2nd Annual COPD Conference Miami Hilton Downtown, July 17-19, 2015 Patient Centered Cross-Continuum Education to Improve the Care of Patients with COPD 3
... who had "Tommy John" elbow reconstruction surgery were able to ... to a study released today at the 2008 American Orthopaedic ... Grande Lakes. While reassuring to athletes, the study authors find ... surgery, alarming. , "Before 1997 this surgery was performed on ...
... (CDH) of Winfield, Ill. has been ranked #47 in ... accessible today online,at http://www.usnews.com/besthospitals and on sale ... 5,453 hospitals reviewed, only 170 medical centers,nationwide ranked high ... listed in one or more of the 16 specialties., ...
... 11 In a letter to the,Senate, forty-five ... to address critical shortfalls in legislation that would,reauthorize ... the Senate,poised to vote on a five-year, $50 ... to "both set and correct policies based,on evidence ...
... Calif., July 11 A,democratic process involving several SEIU ... with hearings to determine the best way to unite,long-term ... greatest strength,to win for their families and the clients ... a thorough, open, and democratic,discussion to make sure that ...
... no difference, study finds , , FRIDAY, July 11 (HealthDay ... developing breast cancer do not seem to improve even ... the disease, a new report says. , Scientists have ... small but statistically significant increase in the risk of ...
... Zen at Zoe's Garden, a new Baltimore wellness center offering massage ... in Fells Point. , ... Baltimore, MD (PRWEB) July ... wellness center offering massage therapy, acupuncture, yoga instruction , ...
Cached Medicine News:Health News:Dramatic increase in 'Tommy John' surgery in young patients cause for concern 2Health News:Central DuPage Hospital's Orthopedics Ranks in U.S. News Media Group's 2008 Edition of America's Best Hospitals for the Second Consecutive Year 2Health News:Central DuPage Hospital's Orthopedics Ranks in U.S. News Media Group's 2008 Edition of America's Best Hospitals for the Second Consecutive Year 3Health News:Putting Health Before Politics: How the United States Senate Can Fix Global HIV/AIDS Funding 2Health News:Putting Health Before Politics: How the United States Senate Can Fix Global HIV/AIDS Funding 3Health News:Putting Health Before Politics: How the United States Senate Can Fix Global HIV/AIDS Funding 4Health News:Putting Health Before Politics: How the United States Senate Can Fix Global HIV/AIDS Funding 5Health News:Recent Genetic Discoveries Don't Improve Prediction of Breast Cancer 2Health News:Baltimore Wellness Center "Zen at Zoe's Garden" Launches in Baltimore's Fells Point 2
Spurling-Kerrison (Colclough) Laminectomie Rongeur. 15 cm - 6, thick footplate, large handle, 40 up-cutting, jaws 3 mm wide....
Kerrison (Micro) Laminectomie Rongeur, with ejector. 18 cm - 7 1/8, with thick footplate, small handle, 90 up-cutting, jaws 2 mm wide....
... The Tangent Posterior Impacted Instrument Set offers ... of the advantages offered by the Tangent ... preparation and the ability to reproduce the ... to ensure proper vertebral body distraction. A ...
Regulates physiological flow within normal ranges of Intraventricular Pressure (IVP) in the supine, sitting or standing position....
Medicine Products: